The Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016 Deep Market Research Report is a professional and in-depth study on the current state of the Dental Implants industry.
The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Dental Implants market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.
Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.
The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Dental Implants industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.
With 161 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Table Of Contents
1 Industry Overview 1
1.1 Basic Information of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 1
1.1.1 Definition of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 1
1.1.2 Segments of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2
1.1.3 Applications of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 3
1.1.4 Characteristics of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 4
1.2 Development Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 4
1.3 Enter Barriers Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 5
2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International and China Market Analysis 8
2.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry International Market Analysis 8
2.1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International Market Development History 8
2.1.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Competitive Landscape Analysis 9
2.1.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International Main Regions Development Status 10
2.1.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International Market Development Trend 11
2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry China Market Analysis 12
2.2.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications China Market Development History 12
2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications China Main Regions Development Status 13
2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International and China Market Comparison Analysis 13
3 Environment Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 14
3.1 International Economy Analysis 14
3.2 China Economy Analysis 18
3.3 Policy Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20
3.4 News Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20
4 Analysis of Revenue by Segments 22
4.1 Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 22
4.2 Global Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 26
4.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27
5 Analysis of Revenue by Regions and Applications 29
5.1 Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2011-2016 29
5.2 2011-2016 North America Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 33
5.3 2011-2016 Europe Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 34
5.4 2011-2016 Japan Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 35
5.5 2011-2016 China Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 36
6 Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Status 2011-2016 37
6.1 Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 37
6.2 Revenue Market Share Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 39
6.3 Revenue Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 47
6.4 Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 48
7 Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Key Players 52
7.1 Roche 52
7.1.1 Company Profile 52
7.1.2 Revenue and Gross Margin 53
7.1.3 Roche SWOT Analysis 53
7.2Dako (Agilent Technologies) 54
7.2.1 Company Profile 54
7.2.2 Revenue and Gross Margin 55
7.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 56
7.3 Merck 56
7.3.1 Company Profile 56
7.3.2 Revenue and Gross Margin 57
7.3.3 Merck SWOT Analysis 58
7.4 BD 59
7.4.1 Company Profile 59
7.4.2 Product Picture and Specifications 60
7.1.3 Revenue and Gross Margin 60
7.4.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 61
7.5 Abbott 62
7.5.1 Company Profile 62
7.5.2 Product Picture and Specifications 63
7.5.3 Revenue and Gross Margin 63
7.5.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 64
7.6 Genesys Biolabs (20/20GeneSystems) 65
7.6.1 Company Profile 65
7.6.2 Revenue and Gross Margin 66
7.6.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 67
7.7 Affymetrix 67
7.7.1 Company Profile 67
7.7.2 Product Picture and Specifications 68
7.7.3 Revenue and Gross Margin 69
7.7.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 70
7.8 Agendia 71
7.8.1 Company Profile 71
7.8.2 Product Picture and Specifications 72
7.8.3 Revenue and Gross Margin 73
7.8.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 74
7.9 ALMAC 74
7.9.1 Company Profile 74
7.9.2 Revenue and Gross Margin 75
7.9.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 76
7.10 Arrayit 77
7.10.1 Company Profile 77
7.10.2 Revenue and Gross Margin 78
7.10.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 79
7.11 Biocartic 79
7.11.1 Company Profile 79
7.11.2 Product Picture and Specifications 80
7.11.3 Revenue and Gross Margin 81
7.11.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 82
7.12 BG Medicine 82
7.12.1 Company Profile 82
7.12.2 Product Picture and Specifications 83
7.12.3 Revenue and Gross Margin 83
7.12.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 84
7.13 KEGG EXPRESSION Database 85
7.13.1 Company Profile 85
7.13.3 Revenue and Gross Margin 86
7.13.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 87
7.14 Thermo Fisher 87
7.14.1 Company Profile 87
7.14.2 Product Picture and Specifications 88
7.14.3 Revenue and Gross Margin 88
7.14.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 89
7.15 BGI 90
7.15.1 Company Profile 90
7.15.2 Revenue and Gross Margin 91
7.15.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 92
8 Sales Price and Gross Margin Analysis 94
8.1 Analysis of Cost, Gross and Gross margin 94
8.1.1 Cost Analysis 94
8.2 Gross Margin Analysis 94
9 Marketing Trader or Distributor Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 96
9.1 Marketing Channels Status of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 96
9.2 Business Model of Commercializing Biomarkers Service Supplier 97
10 Development Trend of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016-2021 98
10.1 Revenue Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021 98
10.2 Gross Margin Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021 100
11 Industry Chain Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101
11.1 Equipment Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101
11.2 Major Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101
11.3 Key Consumers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 102
11.4 Supply Chain Relationship Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 103
12 New Project SWOT Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 105
13 Conclusion of the Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016 106
List Of Tables and Figures
Figure some techniques of biological markers for research 2
Table Segments of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2
Table, the characteristics of biomarkers and related industry 4
Table Global Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players 5
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Development History 8
Figure Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 9
Figure Global Major Player Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2015 10
Figure Global Main Regions Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2015 11
Figure Pre-competitive collaboration can help expand published shared knowledge 11
Figure China Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2015 12
Table China Main Regions Development Status 13
Figure Global & China Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 13
Figure Global GDP Map 2014 14
Figure USA GDP Change 2005-2014 15
Figure USA CPI Change 2011-2015 15
Figure EU GDP Change 2005-2014 16
Figure German CPI Change 2011-2015 16
Figure UK CPI Change 2011-2015 17
Figure Japan GDP Change 2005-2014 17
Figure Japan CPI Change 2005-2014 18
Figure China GDP Change 2005-2014 18
Figure China CPI Change 2005-2014 19
Figure China PPI Growth Rate 2005-2014 19
Table Policy of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20
Table Industry News 1 of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20
Table Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 (M USD) 22
Table Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 22
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2011 23
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2012 23
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2013 24
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2014 24
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2015 25
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2016 25
Figure Global Revenue Growth Rate of Consumables 2011-2016 26
Figure Global Revenue Growth Rate of Services 2011-2016 26
Figure Global Revenue Growth Rate of Software 2011-2016 27
Table North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27
Table Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27
Table China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 28
Table Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2011-2016 (M USD) 29
Table Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2011-2016 29
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2011 30
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2012 30
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2013 31
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2014 31
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2015 32
Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2016 32
Table North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 33
Figure North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 33
Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 34
Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 34
Table Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 35
Figure Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 35
Table China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 36
Figure China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 36
Table Global and China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue of 2011-2016 (M USD) 37
Table Global and China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share of 2011-2016 37
Table China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue of 2011-2016 (M USD) 38
Table China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share of 2011-2016 38
Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2011 39
Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2012 40
Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2013 41
Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2014 42
Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2015 43
Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2016 44
Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2011 44
Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2012 45
Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2013 45
Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2014 46
Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2015 46
Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2016 47
Figure Global Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 47
Figure China Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 48
Figure 2011-2016 Global and China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Comparison 48
Table Cost of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players 2011-2016 (M USD) 48
Table Gross of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players 2011-2016 (M USD) 49
Table Gross Margin of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players 2011-2016 50
Figure Gross Margin of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players in 2014 51
Table Roche Company Profile List 52
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Roche 2011-2016 53
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Roche 2011-2016 53
Table Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 53
Table Dako (Agilent Technologies) Information List 54
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 55
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 55
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 56
Table Merck Company Profile List 56
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Merck 2011-2016 57
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Merck 2011-2016 58
Table Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 58
Table BD Information List 59
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of BD 60
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 60
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 61
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 61
Table Abbott Information List 62
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture 63
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 63
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 64
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 64
Table Genesys Biolabs(20/20GeneSystems) Information List 65
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 66
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 66
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 67
Table Affymetrix Information List 67
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Affymetrix 68
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 69
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 70
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 70
Table Agendia Information List 71
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Agendia 72
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 73
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 73
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 74
Table ALMAC Information List 74
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 75
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 76
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 76
Table Arrayit Information List 77
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 78
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 78
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 79
Table Biocartic Information List 79
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Biocartic 80
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 81
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 81
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 82
Table BG Medicine Information List 82
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of BG Medicine 83
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 83
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 84
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 84
Table KEGG EXPRESSION Database Information List 85
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 86
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 86
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 87
Table Thermo Fisher Information List 87
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Thermo Fisher 88
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 88
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 89
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 89
Table BGI Information List 90
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 91
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 92
Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 92
Table Cost Analysis 94
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufactor Profit Model 94
Figure Marketing Channels Status of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 96
Figure Business Model of Commercializing Biomarkers Service Supplier 97
Figure Global Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021 98
Figure China Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021 99
Figure Global and China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Comparison 2016-2021 99
Figure Gross Margin 2016-2021 100
Table Equipment Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101
Table Major Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101
Table Key Consumers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 102
Figure Biomarkers connect bench to bedside and create a continuous feedback loop for innovation. 103
Figure Data standards and semantics enable continuous information flow across industries. 104
Table New Project SWOT Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 105
Table Pharmacogenomic Biomarkers in Drug Labeling 111
